These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 16732291)

  • 1. Fas-ligand-mediated paracrine T cell regulation by the receptor NKG2D in tumor immunity.
    Groh V; Smythe K; Dai Z; Spies T
    Nat Immunol; 2006 Jul; 7(7):755-62. PubMed ID: 16732291
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of the NKG2D ligand UL16 binding protein-1 (ULBP-1) on dendritic cells.
    Schrama D; Terheyden P; Otto K; Kämmerer U; Bröcker EB; Lühder F; Cosman D; Andersen MH; Becker JC
    Eur J Immunol; 2006 Jan; 36(1):65-72. PubMed ID: 16342232
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Soluble ULBP suppresses natural killer cell activity via down-regulating NKG2D expression.
    Song H; Kim J; Cosman D; Choi I
    Cell Immunol; 2006 Jan; 239(1):22-30. PubMed ID: 16630603
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Up-regulation of inhibitory natural killer receptors CD94/NKG2A with suppressed intracellular perforin expression of tumor-infiltrating CD8+ T lymphocytes in human cervical carcinoma.
    Sheu BC; Chiou SH; Lin HH; Chow SN; Huang SC; Ho HN; Hsu SM
    Cancer Res; 2005 Apr; 65(7):2921-9. PubMed ID: 15805295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NKG2D-mediated antitumor activity by tumor-infiltrating lymphocytes and antigen-specific T-cell clones isolated from melanoma patients.
    Maccalli C; Nonaka D; Piris A; Pende D; Rivoltini L; Castelli C; Parmiani G
    Clin Cancer Res; 2007 Dec; 13(24):7459-68. PubMed ID: 18094430
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generation of antitumor responses by genetic modification of primary human T cells with a chimeric NKG2D receptor.
    Zhang T; Barber A; Sentman CL
    Cancer Res; 2006 Jun; 66(11):5927-33. PubMed ID: 16740733
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Proteolytic release of soluble UL16-binding protein 2 from tumor cells.
    Waldhauer I; Steinle A
    Cancer Res; 2006 Mar; 66(5):2520-6. PubMed ID: 16510567
    [TBL] [Abstract][Full Text] [Related]  

  • 8. TGF-beta and metalloproteinases differentially suppress NKG2D ligand surface expression on malignant glioma cells.
    Eisele G; Wischhusen J; Mittelbronn M; Meyermann R; Waldhauer I; Steinle A; Weller M; Friese MA
    Brain; 2006 Sep; 129(Pt 9):2416-25. PubMed ID: 16891318
    [TBL] [Abstract][Full Text] [Related]  

  • 9. NKG2D ligands: key targets of the immune response.
    González S; López-Soto A; Suarez-Alvarez B; López-Vázquez A; López-Larrea C
    Trends Immunol; 2008 Aug; 29(8):397-403. PubMed ID: 18602338
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression and function of NKG2D in CD4+ T cells specific for human cytomegalovirus.
    Sáez-Borderías A; Gumá M; Angulo A; Bellosillo B; Pende D; López-Botet M
    Eur J Immunol; 2006 Dec; 36(12):3198-206. PubMed ID: 17109473
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Exosomes and the MICA-NKG2D system in cancer.
    Clayton A; Tabi Z
    Blood Cells Mol Dis; 2005; 34(3):206-13. PubMed ID: 15885603
    [TBL] [Abstract][Full Text] [Related]  

  • 12. NKG2D ligands in tumor immunity.
    Nausch N; Cerwenka A
    Oncogene; 2008 Oct; 27(45):5944-58. PubMed ID: 18836475
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chimeric NKG2D modified T cells inhibit systemic T-cell lymphoma growth in a manner involving multiple cytokines and cytotoxic pathways.
    Zhang T; Barber A; Sentman CL
    Cancer Res; 2007 Nov; 67(22):11029-36. PubMed ID: 18006849
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Different expression of Fas and Fas ligand in tumor infiltrating and peripheral lymphocytes of patients with renal cell carcinomas.
    Elsässer-Beile U; Gierschner D; Welchner T; Wetterauer U
    Anticancer Res; 2003; 23(1A):433-7. PubMed ID: 12680244
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Downregulation and/or release of NKG2D ligands as immune evasion strategy of human neuroblastoma.
    Raffaghello L; Prigione I; Airoldi I; Camoriano M; Levreri I; Gambini C; Pende D; Steinle A; Ferrone S; Pistoia V
    Neoplasia; 2004; 6(5):558-68. PubMed ID: 15548365
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Expansion of circulating NKG2D+ effector memory T-cells and expression of NKG2D-ligand MIC in granulomaous lesions in Wegener's granulomatosis.
    Capraru D; Müller A; Csernok E; Gross WL; Holl-Ulrich K; Northfield J; Klenerman P; Herlyn K; Holle J; Gottschlich S; Voswinkel J; Spies T; Fagin U; Jabs WJ; Lamprecht P
    Clin Immunol; 2008 May; 127(2):144-50. PubMed ID: 18313361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Differing phenotypes between intraepithelial and stromal lymphocytes in early-stage tongue cancer.
    Katou F; Ohtani H; Watanabe Y; Nakayama T; Yoshie O; Hashimoto K
    Cancer Res; 2007 Dec; 67(23):11195-201. PubMed ID: 18056444
    [TBL] [Abstract][Full Text] [Related]  

  • 18. CD4+NKG2D+ T cells in Crohn's disease mediate inflammatory and cytotoxic responses through MICA interactions.
    Allez M; Tieng V; Nakazawa A; Treton X; Pacault V; Dulphy N; Caillat-Zucman S; Paul P; Gornet JM; Douay C; Ravet S; Tamouza R; Charron D; Lémann M; Mayer L; Toubert A
    Gastroenterology; 2007 Jun; 132(7):2346-58. PubMed ID: 17570210
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blockade of NKG2D signaling prevents the development of murine CD4+ T cell-mediated colitis.
    Ito Y; Kanai T; Totsuka T; Okamoto R; Tsuchiya K; Nemoto Y; Yoshioka A; Tomita T; Nagaishi T; Sakamoto N; Sakanishi T; Okumura K; Yagita H; Watanabe M
    Am J Physiol Gastrointest Liver Physiol; 2008 Jan; 294(1):G199-207. PubMed ID: 17962357
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mutual activation of CD4+ T cells and monocytes mediated by NKG2D-MIC interaction requires IFN-gamma production in systemic lupus erythematosus.
    Yang D; Wang H; Ni B; He Y; Li J; Tang Y; Fu X; Wang Q; Xu G; Li K; Yang Z; Wu Y
    Mol Immunol; 2009 Apr; 46(7):1432-42. PubMed ID: 19200602
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.